CTIS2024-514870-29-00
Active, not recruiting
Phase 1
A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human a-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hurler variant
Ospedale San Raffaele S.r.l.0 sites8 target enrollmentJune 11, 2024
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Mucopolysaccharidosis type I Hurler
- Sponsor
- Ospedale San Raffaele S.r.l.
- Enrollment
- 8
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Written informed consent by parent/legal guardian, Sex: Males or Females, Age: \= 28 days and \= 11 years old, Biochemically and molecularly proven MPS IH, Lansky Index \> 80 %, Indication to HSCT, Lack of a non\-heterozygous (for mutated IDUA) HLA\-matched sibling donor or a \=7/8 (4 digits high\-resolution typing) HLA\-matched cord blood donor with a cellularity \=5 x 107 Total Nucleated Cells (TNC)/Kg after 1\-month search. This criterion will not apply to patients whose country of origin does not offer unrelated donor cord blood transplantation., Adequate cardiac, renal, hepatic and pulmonary functions
Exclusion Criteria
- •Use of other investigational agents within 4 weeks prior to study enrolment (within 6 weeks if use of long\-acting agents), Controindications to PeIMP (G\-CSF, Plerixafor, Busulfan, Fludarabine, Rituximab), Severe, active viral, bacterial, or fungal infection at eligibility evaluation, Patients affected by malignant neoplasia or family history of familial cancer syndromes, Cytogenetic alterations associated with high risk of developing hematological malignancies, History of uncontrolled seizures, Patients with end\-organ damage or any other severe disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study, Positivity for HIV (serology or RNA), and/or HbsAg and/or HBV DNA and/or HCV RNA and/or Treponema Pallidum or Mycoplasma active infection, Patients with DQ/IQ \<70 (Cognitive Scale for Bayley Scale of Infant Development and Performance IQ for wppsi and wisc), Previous allogeneic HSCT or gene therapy with a different product
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Gene therapy study with autologous hemapoietic stem cells for patients affected by MPSIHEUCTR2017-002430-23-ITOSPEDALE SAN RAFFAELE6
Active, not recruiting
Phase 1
Studio di terapia genica con cellule staminali ematopoietiche autologheEUCTR2014-004860-39-ITOSPEDALE SAN RAFFAELE10
Active, not recruiting
Phase 1
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 20.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-003084-37-CZSOTIO a.s.98
Active, not recruiting
Phase 1
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-003084-37-SKSOTIO a.s.98
Completed
Phase 1
A clinical trial to study safety and effects of P276-00 in combination with Gemcitabine in treatment of pancreatic cancer .CTRI/2009/091/000214Piramal Life Sciences Limited23